DAVIS, Calif., April 30, 2018 -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce that Grandevo CG® and Venerate CG®, have been approved for use on Cannabis by the Colorado, Nevada, and Washington Departments of Agriculture.
The active ingredients in Venerate CG and Grandevo CG bioinsecticides/miticides are each new species of non-living bacteria, with insecticidal and miticidal properties. Both products feature multiple modes of action that are complementary to one another. This complex activity makes the products excellent additions to insect and mite management programs, which allows the two products to be used on a standalone basis, or in conjunction in a rotational crop protection program. In addition, both products can be used right up to harvest and have the shortest re-entry period (4 hours). Cannabis growers have been adopting Venerate CG and Grandevo CG for control of spider mites, bud mites, thrips and aphids.
"Grandevo and Venerate are a game changer when it comes to IPM programs. I have eliminated all other preventive sprays and only use Grandevo and Venerate. I have had great results against all types of malicious bugs, from leaf eaters to root aphids these products have kept my gardens clean and my beneficial bugs happy,” said Kyle Stamback of Lean Cultivation, NorthWestGrown i502.
“We are pleased that the Colorado, Nevada and Washington Departments of Agriculture determined that Grandevo CG and Venerate CG meets their state’s criteria for use on Cannabis, and we look forward to working with growers and distributors to serve these exciting new markets with our existing product portfolio as well as our future innovations,” stated Lisa Malabad, Cannabis Segment Lead at Marrone Bio Innovations.
About Marrone Bio Innovations
Bio With Bite.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM and AmplitudeTM, ZeltoTM and Zequanox®. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential of Grandevo and Venerate CG and other MBI products in the Cannabis market, market projections, including the potential benefits of Grandevo and Venerate CG. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise.
Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Keith Pitts, Sr. VP of Regulatory and Government Affairs and Chief Sustainability Officer
Lisa Malabad, Product Marketing Manager and Cannabis Segment Lead
Telephone: +1 (530) 750-2800
Email: [email protected]
MBI Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
[email protected]
www.mzgroup.us


Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
BHP Attracts AI-Focused Investors as Copper Demand Surges
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 



